Raphael Pharmaceutical Net Income
| RAPH Stock | 1.40 0.00 0.00% |
As of the 1st of February, Raphael Pharmaceutical holds the Variance of 128.2, coefficient of variation of 1175.1, and Risk Adjusted Performance of 0.0709. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Raphael Pharmaceutical, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for eleven technical drivers for Raphael Pharmaceutical, which can be compared to its competitors.
Raphael Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Raphael Pharmaceutical's valuation are provided below:Raphael Pharmaceutical does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Raphael |
Raphael Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Raphael Pharmaceutical's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Raphael Pharmaceutical.
| 11/03/2025 |
| 02/01/2026 |
If you would invest 0.00 in Raphael Pharmaceutical on November 3, 2025 and sell it all today you would earn a total of 0.00 from holding Raphael Pharmaceutical or generate 0.0% return on investment in Raphael Pharmaceutical over 90 days. Raphael Pharmaceutical is related to or competes with Voyageur Pharmaceuticals, Avicanna, and Mydecine Innovations. More
Raphael Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Raphael Pharmaceutical's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Raphael Pharmaceutical upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0811 | |||
| Maximum Drawdown | 86.67 |
Raphael Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Raphael Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Raphael Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Raphael Pharmaceutical historical prices to predict the future Raphael Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0709 | |||
| Jensen Alpha | 0.9724 | |||
| Total Risk Alpha | 0.4065 | |||
| Treynor Ratio | (1.76) |
Raphael Pharmaceutical February 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0709 | |||
| Market Risk Adjusted Performance | (1.75) | |||
| Mean Deviation | 2.68 | |||
| Coefficient Of Variation | 1175.1 | |||
| Standard Deviation | 11.32 | |||
| Variance | 128.2 | |||
| Information Ratio | 0.0811 | |||
| Jensen Alpha | 0.9724 | |||
| Total Risk Alpha | 0.4065 | |||
| Treynor Ratio | (1.76) | |||
| Maximum Drawdown | 86.67 | |||
| Skewness | 6.91 | |||
| Kurtosis | 54.64 |
Raphael Pharmaceutical Backtested Returns
Raphael Pharmaceutical appears to be out of control, given 3 months investment horizon. Raphael Pharmaceutical maintains Sharpe Ratio (i.e., Efficiency) of 0.0851, which implies the firm had a 0.0851 % return per unit of risk over the last 3 months. By analyzing Raphael Pharmaceutical's technical indicators, you can evaluate if the expected return of 0.96% is justified by implied risk. Please evaluate Raphael Pharmaceutical's Coefficient Of Variation of 1175.1, variance of 128.2, and Risk Adjusted Performance of 0.0709 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Raphael Pharmaceutical holds a performance score of 6. The company holds a Beta of -0.54, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Raphael Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Raphael Pharmaceutical is likely to outperform the market. Please check Raphael Pharmaceutical's jensen alpha and rate of daily change , to make a quick decision on whether Raphael Pharmaceutical's historical price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Raphael Pharmaceutical has no correlation between past and present. Overlapping area represents the amount of predictability between Raphael Pharmaceutical time series from 3rd of November 2025 to 18th of December 2025 and 18th of December 2025 to 1st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Raphael Pharmaceutical price movement. The serial correlation of 0.0 indicates that just 0.0% of current Raphael Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.73 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Raphael Pharmaceutical reported net income of (1.62 Billion). This is much lower than that of the sector and significantly lower than that of the Net Income industry. The net income for all United States stocks is notably higher than that of the company.
Raphael Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Raphael Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Raphael Pharmaceutical could also be used in its relative valuation, which is a method of valuing Raphael Pharmaceutical by comparing valuation metrics of similar companies.Raphael Pharmaceutical is currently under evaluation in net income category among its peers.
Raphael Fundamentals
| Return On Asset | -19.04 | |||
| Shares Outstanding | 15.62 M | |||
| EBITDA | (1.63 B) | |||
| Net Income | (1.62 B) | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.42 M) | |||
| Market Capitalization | 17.19 M | |||
| Total Asset | 422 K | |||
| Net Asset | 422 K |
About Raphael Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Raphael Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Raphael Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Raphael Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VGIAX | Vanguard Growth And | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| ASML | ASML Holding NV |
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.